PD-L1 Antibody (Immunohistochemistry)

PD-L1 Antibody (Immunohistochemistry)

The PD-L1 (Programmed Death Ligand 1) Antibody is a critical immunohistochemical marker in immuno-oncology, used to evaluate patient response to immune checkpoint inhibitor therapies such as Pembrolizumab and Nivolumab.
PD-L1, also known as B7-H1 or CD274, is a 40 kDa type I transmembrane glycoprotein belonging to the B7 family.
It binds to the PD-1 receptor on activated T and B lymphocytes, NK cells, and dendritic cells, leading to inhibition of immune activation and tumor immune evasion.

PD-L1 is expressed in multiple tumor types, including lung, breast, colon, ovarian, renal cell carcinoma, and melanoma.
Positive IHC staining appears as membranous and cytoplasmic brown coloration, and its intensity and percentage are key for guiding immunotherapy decisions.

🔬 Features and Benefits PD-L1 Antibody

• Essential marker for predicting immunotherapy response

• Distinct brown membranous/cytoplasmic staining

• Applicable across multiple tumor types (lung, colon, melanoma, renal, breast)

• Compatible with standard IHC and automated platforms

• Excellent stability: 18-month shelf life at 2–8 °C

💡 Diagnostic Applications

• Detection of PD-L1 expression in NSCLC, melanoma, RCC, breast, and GI tumors

• Selection of candidates for anti–PD-1 / anti–PD-L1 therapies

• Research in tumor immunology and immune evasion mechanisms

• Evaluation of tumor microenvironment immune activity

🌐 Fardad Azma Rad Co.

Fardad Azma Rad Co., the exclusive representative of Talent Biomedical in Iran, supplies premium-quality immunohistochemistry antibodies, including PD-L1.
With a focus on scientific accuracy, diagnostic reliability, and international quality compliance, the company supports pathology and molecular diagnostic laboratories throughout Iran.

“Download Brochure”